InsiderTrades.com logo
Jeffrey Alan Jones net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeffrey Jones Biography and Net Worth

Chief Medical Officer of Cullinan Therapeutics

Dr. Jeffrey Jones has over 15 years of clinical development experience in academia and industry, with skills ranging from clinical trials, drug development, medical education, and healthcare management. Previously, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at Bristol Myers Squibb, where he led the development and life cycle management strategy for Reblozyl®. Earlier, Dr. Jones was Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development at Celgene, where he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development.

Before joining the industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, an M.P.H. from the University of Texas School of Public Health and an M.D. from the University of Michigan Medical School, completing his residency in internal medicine at McGill University.

What is Jeffrey Alan Jones' net worth?

The estimated net worth of Jeffrey Alan Jones is at least $1.84 million as of February 25th, 2025. Dr. Jones owns 174,164 shares of Cullinan Therapeutics stock worth more than $1,842,655 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Jones may own. Additionally, Dr. Jones receives a salary of $780,320.00 as Chief Medical Officer at Cullinan Therapeutics. Learn More about Jeffrey Alan Jones' net worth.

How old is Jeffrey Alan Jones?

Dr. Jones is currently 53 years old. There are 6 older executives and no younger executives at Cullinan Therapeutics. The oldest executive at Cullinan Therapeutics is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Jeffrey Alan Jones' age.

What is Jeffrey Alan Jones' salary?

As the Chief Medical Officer of Cullinan Therapeutics, Inc., Dr. Jones earns $780,320.00 per year. The highest earning executive at Cullinan Therapeutics is Mr. Nadim Ahmed, President, CEO & Director, who commands a salary of $1,160,000.00 per year. Learn More on Jeffrey Alan Jones' salary.

How do I contact Jeffrey Alan Jones?

The corporate mailing address for Dr. Jones and other Cullinan Therapeutics executives is , , . Cullinan Therapeutics can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Jeffrey Alan Jones' contact information.

Has Jeffrey Alan Jones been buying or selling shares of Cullinan Therapeutics?

Jeffrey Alan Jones has not been actively trading shares of Cullinan Therapeutics during the last ninety days. Most recently, Jeffrey Alan Jones sold 4,895 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a transaction totalling $41,754.35. Following the completion of the sale, the insider now directly owns 174,164 shares of the company's stock, valued at $1,485,618.92. Learn More on Jeffrey Alan Jones' trading history.

Who are Cullinan Therapeutics' active insiders?

Cullinan Therapeutics' insider roster includes Nadim Ahmed (Pres), Nadim Ahmed (President and Chief Executive Officer), Ansbert Gadicke (Director), Jeffrey Jones (Chief Medical Officer), Jennifer Michaelson (Insider), Corrine Savill (Chief Business Officer), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Therapeutics' active insiders.

Are insiders buying or selling shares of Cullinan Therapeutics?

During the last twelve months, Cullinan Therapeutics insiders bought shares 8 times. They purchased a total of 1,874,057 shares worth more than $13,325,286.34. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 42,006 shares worth more than $444,804.13. The most recent insider tranaction occured on November, 24th when insider Jennifer Michaelson sold 4,000 shares worth more than $49,200.00. Insiders at Cullinan Therapeutics own 7.2% of the company. Learn More about insider trades at Cullinan Therapeutics.

Information on this page was last updated on 11/24/2025.

Jeffrey Alan Jones Insider Trading History at Cullinan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2025Sell4,895$8.53$41,754.35174,164View SEC Filing Icon  
12/21/2023Sell1,860$8.50$15,810.0056,191View SEC Filing Icon  
12/18/2023Sell386$8.22$3,172.9258,051View SEC Filing Icon  
6/20/2023Sell387$12.94$5,007.7858,437View SEC Filing Icon  
4/18/2023Sell392$10.71$4,198.3259,218View SEC Filing Icon  
3/20/2023Sell390$11.32$4,414.8059,610View SEC Filing Icon  
See Full Table

Jeffrey Alan Jones Buying and Selling Activity at Cullinan Therapeutics

This chart shows Jeffrey Alan Jones's buying and selling at Cullinan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Therapeutics Company Overview

Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.58
Low: $10.08
High: $10.79

50 Day Range

MA: $8.26
Low: $5.75
High: $12.93

2 Week Range

Now: $10.58
Low: $5.68
High: $13.60

Volume

877,985 shs

Average Volume

1,211,674 shs

Market Capitalization

$625.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A